Researchers start liraglutide study for Alzheimer's; Globe features new Novartis immuno-oncology effort;

@FierceBiotech: Shifting positions, Genervon now says it has yet to file for ALS drug OK. Editor's corner | Follow @FierceBiotech

@JohnCFierce: Gene therapy player Dimension stirs IPO buzz with $65M venture round
(we talked with CEO Annalisa Jenkins). Article | Follow @JohnCFierce

@DamianFierce: $TEVA bids $82 per share on $MYL. Release | Follow @DamianFierce

> Investigators have launched a clinical trial to see if Novo's ($NVO) diabetes drug Victoza (liraglutide) can slow the advance of Alzheimer's in early-stage patients. Report

> The Boston Globe features Novartis's ($NVS) plans to build a new immune-oncology team in Cambridge, MA, under Dr. Glenn Dranoff. Story

Medical Device News

@FierceMedDev: UPDATED: NEA-backed Cartiva raises $6M after a recent FDA nod, as it heads into a PMA review. Report | Follow @FierceMedDev

@VarunSaxena2: Study: Schizophrenics on J&J's injectable fare better than those on oral meds. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: LabCorp rides direct-to-consumer wave with online testing services. FierceDiagnostics story | Follow @EmilyWFierce

> Spirox reels in $18.5M for nasal obstruction device. Article

> Tal Medical gets $14M to sort out dosage, durability for fast-acting depression device. News

Pharma News

@FiercePharma: ICYMI: Gunning for a spot in the next-gen autoimmune market, Lilly med hits goals in latest trial. More | Follow @FiercePharma

@EricPFierce: Daiichi Sankyo appears to have had enough of Indian generics industry. Selling its $3B+ stake in Sun. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: $GSK yanks all doses of quadrivalent flu jab for potency problems. Report | Follow @CarlyHFierce

> Teva has to pay a record-setting $512M to settle pay-for-delay case. Who's next? More

> Ready for a Teva-Mylan scrap? It's here. Teva finally launches its $40B takeover bid. Story

Drug Delivery News

> Icon heralds late-stage success for extended-release, postsurgical cataract treatment. Report

> Nanoparticle coating spurs oral cancer vaccine potential. Story

> Mersana's cancer-fighting antibody-drug conjugate shows promise in animal studies. Article

> 'Doc fix' reform bill alters Medicare reimbursement for some oral-only meds. Item

> Study: Schizophrenics on J&J's injectable fare better than those on oral meds. More

Pharma Manufacturing News

> Pfizer accused of misleading consumers with oversized Advil bottles. Item

> Novasep's 'focus' pays off for contract manufacturer. More

> GSK recalls vaccine made at troubled plant in Canada. News

> Merck injects another $12.4M in its newest vaccine plant. Story

> Daiichi Sankyo sold Ranbaxy's problems to Sun, now cashing in its stake. Article

Pharma Asia News

> India's Glenmark pulls in Singapore's Temasek money via preference shares. News

> China steps up decentralized drug industry regulation, market prices push. Story

> Indian drug firms eye 'paper tiger' status at home, clinical opportunities abroad. More

> Teva, Barr in largest ever pay-for-delay settlement. Article

> South Korea's Kosdaq bubbles along taking small pharma/biotech for a ride. Report

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.